- Home
- MTEK vs NCEL Comparison
MTEK vs NCEL Comparison
Compare MTEK & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTEK | NCEL |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | Israel | Switzerland |
| Employees | N/A | 11 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MTEK | NCEL |
|---|---|---|
| Price | $1.40 | $2.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 216.6K | 24.0K |
| Earning Date | 03-27-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $1.83 |
| 52 Week High | $4.27 | $4.70 |
Technical Indicators
Market Signals| Indicator | MTEK | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 40.91 |
| Support Level | $1.23 | $1.89 |
| Resistance Level | $1.50 | $3.16 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 48.96 | 41.55 |
Price Performance
Historical ComparisonAbout MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.